/Viatris%20Inc%20logo%20on%20building-by%20SSKH-Pictures%20via%20Shutterstock.jpg)
Viatris Inc. (VTRS), with a market cap of $14.13 billion, is a global healthcare company dedicated to providing access to high-quality medicines and healthcare solutions. Headquartered in Canonsburg, Pennsylvania, Viatris is committed to empowering people worldwide to live healthier lives at every stage of life. The company offers a diverse portfolio of prescription medicines, over-the-counter products, and innovative therapeutic solutions, serving patients in many countries.
VTRS shares have underperformed the broader market over the last year. VTRS has gained 13.8% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 18.5%. Also, in 2024, Viatris stock rose 9.6%, lower than SPX's 12.1% rise on a YTD basis.
Zooming in further, VTRS has underperformed the iShares U.S. Pharmaceuticals ETFs (IHE) on a YTD basis. The exchange-traded fund has gained about 11.1% over this period.
VTRS shares fell nearly 5% after the company lowered its full-year revenue forecast to a range of $14.98 billion to $15.48 billion, down from the earlier projection of $15.25 billion to $15.75 billion.
For the current fiscal year, ending in December, analysts expect VTRS' EPS to decline 7.2% year over year to $2.72 on a diluted basis. The company's earnings surprise history is mixed. It beat the consensus estimate in two of the last four quarters while missing the forecast on two other occasions.
Among the seven analysts covering VTRS stock, the consensus rating is a “Hold.” That’s based on one “Strong Buy,” four “Hold” ratings, one “Moderate Sell,” and one “Strong Sell.”
On Jul. 24, David Amsellem from Piper Sandler maintained a “Hold” rating on Viatris, with a price target of $13, implying a potential upside of 9.5% from current levels.
The mean price target of $12.83 represents an 8.1% premium to VTRS’ current price levels. The Street-high price target of $15 suggests an upside potential of 26.4%.
On the date of publication, Rashmi Kumari did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
